Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

Pharmacological inhibition of histone deacetylases (HDACs) has been successfully applied in the treatment of a wide range of disorders, including Parkinson's disease, infection, cardiac diseases, inflammation, and especially cancer. HDAC inhibitors (HDACIs) have been proved to be effective anti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Medicinal research reviews 2015-01, Vol.35 (1), p.63-84
Hauptverfasser:	Zhang, Lei, Han, Yantao, Jiang, Qixiao, Wang, Chunbo, Chen, Xuehong, Li, Xiaoguang, Xu, Fuming, Jiang, Yuqi, Wang, Qiang, Xu, Wenfang
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use bifunctional molecule Cancer Cancer therapies histone deacetylase Histone Deacetylase Inhibitors - therapeutic use Humans inhibitors multitargeted Neoplasms - drug therapy Protein Isoforms - drug effects selectivity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!